A Non-inferiority Study of Eyestil® Plus Multidose Versus Vismed Multi®

Dry Eye Syndromes Clinical Trial

— 047/SI  

Official title:

A Prospective Multicenter, Comparative, Randomized, Double-blind, Non-inferiority Study of Eyestil® Plus Multidose Versus Vismed Multi® in Patients With Moderate to Severe Dry Eye Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03803748
• Other study ID #: 047/SI
• Status: Completed
• Phase: N/A
• Start date: July 17, 2019
• Est. completion date: August 31, 2022

Study information

• Verified date: May 2022
• Source: SIFI SpA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

SIFI SpA had developed Eyestil Plus®. It is sterile eyedrops without preservatives with a physiological pH containing sodium hyaluronate. Its intended purpose is to moisturize, lubricate and protect the ocular surface and gives temporary relief to burning, irritation and dry eye-related discomfort, and other complaints induced, for example, by: prolonged use of either soft, semi rigid or rigid contact lenses; exposure to environmental factors (air conditioning, exposure to solar radiation, wind, smoke, pollution, severe climatic conditions, dust); ocular fatigue caused by studying, working, driving or prolonged exposure to electronic devices.

Eyestil Plus® is CE marked but not available yet in all European countries. Considering the European regulatory change on medical devices - from a Directive (Directive 1993/42/EEC) to a Regulation (MDR 2017/745) that now requires clinical evidence of device performance and safety; SIFI Spa decided to implement the present clinical comparative performance study. The choice of Vismed Multi® as the comparator has been done since it is the current French standard of care treatment for patients with moderate to severe dry eyes.

Description:

The aim of the study is to demonstrate the non-inferiority of Eyestil Plus® compared to Vismed Multi® in terms of clinical performance as detected by a reduction of keratitis lesions objectified by staining tests after 1 month of treatment, in patients with moderate to severe dry eye syndrome with keratoconjunctivitis. Secondly, the study is aimed at evaluating the safety profile of the product and the patients' quality of life.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 96
• Est. completion date: August 31, 2022
• Est. primary completion date: May 2, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients, male or female, of at least 18 years of age at the screening visit

• Patients understanding the study, willing to follow the instructions and providing their written Informed Consent Form to participate

• Patients with moderate up severe dry eye with keratoconjunctivitis sicca diagnosed at least 4 weeks before the screening visit

• Patients using artificial tears at least once a day for at least 4 weeks months before the screening visit*

• Patients with corneal/conjunctival lesions consistent with a diagnosis of keratoconjunctivitis measured by tests of staining: i.e. the overall score of the corneal staining test must be = 3 and = 9 on the 15-point Oxford scale

• And at least one of the following element:

Tear volume decreased: must be either present a Schirmer test = 3 mm and = 9 mm / 5 minutes or the sum of 3 consecutive measurements of the tear film break-up time (TBUT) = 30s for at least one eye An OSDI score =18

• Covered by healthcare insurance.

Exclusion Criteria:

• Patients with medical history of herpetic keratitis, peripheral ulcerative keratitis, sclerites, diabetic retinopathy

• Any systemic disease that is not well controlled for at least 2 months (e.g. lupus, rheumatoid arthritis, thyroiditis…) according to clinical judgment

• Patients using any topical therapies such as non-steroidal anti-inflammatory drugs, cortisone, cyclosporine, vasoconstrictor

• Patients with at least one of the following concomitant ocular inflammatory disease:

Stevens Johnson Disease, Atopic Keratoconjunctivitis; Scarlet Eye Pemphigoid

• Patients with anomalies of the eyelid, sucking, infectious conjunctivitis, pterygia, and/or a glaucoma treated with eyedrops

• Presence of graft versus host disease (GVHD)

• Patients who have undergone surgery in the eye, within three months before the study enrolment

• Patients who have undergone corneal transplantation or refractive surgery or plan to undergo any eye surgery in the next four months

• Patients with known or suspected eye allergy

• Patients with a condition or history that, in the opinion of the investigator, may interfere significantly with the subject's participation in the study

• Female pregnant, planning a pregnancy during the study period and nursing an infant

• Patients who are participating or have participated in other clinical trial with investigational drug or device within 30 days prior to screening

• Patients unable to be compliant with the study procedures and requirements, according to the opinion of the investigator

• Patient deprived of liberty by a judicial or administrative decision, or who is under a measure of legal protection (e.g. guardianship or curatorship).

Related Conditions & MeSH terms

• Dry Eye Syndromes
• Keratoconjunctivitis Sicca
• Syndrome

Intervention

Device:
• Eyestil Plus®
• To demonstrate the non-inferiority of Eyestil Plus® compared to Vismed Multi® in terms of clinical performance as detected by a reduction of keratitis lesions objectified by staining tests after 1 month of treatment, in patients with moderate to severe dry eye syndrome with keratoconjunctivitis

Locations

Country	Name	City	State
France	CHU de Bordeaux - Hôpital Pellegrin	Bordeaux
France	Chu Morvan	Brest
France	CHU François Mitterand	Dijon
France	Hôpital de la Croix Rousse	Lyon
France	Centre Monticelli	Marseille
France	Hopital La Timone Adultes	Marseille
France	CHU de Nice - Hôpital Pasteur	Nice
France	CHU Saint Etienne/Hôpital Nord	Saint-Étienne
France	Hopital Bretonneau	Tours
Spain	Instituto Oftalmologico Fernandez-Vega	Madrid
Spain	Hospital Universitario Virgen Macarena	Sevilla
Spain	Hospital Recoletas Campo Grande	Valladolid

Sponsors (1)

Lead Sponsor	Collaborator
SIFI SpA

Countries where clinical trial is conducted

France,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary endpoint/clinical performance by Oxford scale	the between-group comparison of the average variation of the global fluorescein corneal and lissamine green conjunctival staining using the Oxford scale (0 to 15). This refers to the average variation between both timepoints of the Global Ocular Staining Score of the study eye (GOSS) and the comparison between both treatment groups. 0-5 cornea; 0-5 temporal conjuctiva; 0-5 nasal conjunctiva. Max total score: 15	between Day 1 and Day 35 ±4
Secondary	secondary endpoint/clinical performance by TBUT test	The between-group comparisons of the average variation of the time obtained at the TBUT test. This full procedure will be performed 3 times per eye and per time point. At screening and at baseline visits, the sum of these 3 times for at least one eye to be eligible must be = 30 seconds.; Conventionally TBUT's measures shorter than 10 seconds can be referred to tear film instability and measures shorter than 5 seconds, usually, are undoubtable sign of dry eye. The longer it takes, the more stable the tear film. A short TBUT is a sign of poor tear film. A positive number change from baseline indicates an increase in TBUT (improvement) and a negative number change from baseline indicates a decrease in TBUT (worsening).	between Day 1 and Day 35 ±4 and Day 1 and Day 84 ±7
Secondary	secondary endpoint/clinical performance by Oxford scale	The between-group comparison of the average variation of the global fluorescein corneal and lissamine green conjunctival staining using the Oxford scale. This refers to the average variation between both time points of the Global Ocular Staining Score of the study eye (GOSS) and the comparison between both treatment groups. 0-5 cornea; 0-5 temporal conjuctiva; 0-5 nasal conjunctiva. Max total score: 15	between Day 1 and Day 84 ±7 days
Secondary	secondary endpoint/clinical performance by Schirmer Test	The between-group comparisons of the average variation of the paper length obtained at the Schirmer test. The Schirmer test without anesthesia will be here performed to measure the rate of secretion of tears produced by the study eye over 5 minutes.The cut-off value for a severe dry eye in the first one is 6 mm. But the cut-off that will here use will be 9 mm with the following interpretation: Normal = = 10 millimeters (mm) of tears,; Dry Eye = = 9 mm of tears A positive number change from baseline indicates an increase in tears (improvement) and a negative number change from baseline indicates a decrease in tears (worsening).	test between Day 1 and Day 84 ±7
Secondary	secondary endpoint/patient symptoms by Ocular Symptoms Disease Index (OSDI) score	The between-group comparisons of the average variation of Ocular Symptoms Disease Index (OSDI) score. The patient's dry eye symptoms will be assessed with the Ocular Surface Disease Index (OSDI). It is a validated 12-questions scale for patients that covers a broad spectrum of ocular surface symptoms, the severity of such symptoms for patients and how these symptoms affect/impact visual function over a 1-week recall period. Its scores range from 0 to 100, with higher scores indicating greater severity of disease.Positive result is considered when the OSDI score is = 18.To be consistent with the IMD indication, patient with moderate to severe dry eye thus with an OSDI = 18 will be selected. If the patient's OSDI score will be strictly below 18 at the screening or baseline visit, s/he will be considered as a screening failure.	Day 1 and Day 35 ±4 and Day 1 and Day 84 ±7
Secondary	secondary endpoint/patient symptoms by Dry Eye-Related Quality -of-Life(DEQS) questionnaire	The between-group comparisons of the average variation of Dry Eye-Related Quality-of-Life (DEQS) questionnaire. It is a validated 15-item scale divided into 2 subscales related to dry eye symptoms and its influence on daily life: The frequency is scored on a 5-point Likert scale ranging from 0 (no symptom) to 4 (highest frequency).; • The degree is scored on a 4-point Likert scale ranging from 1 to 4, a larger number indicates a greater burden.; The summary score ranges from 0 to 100, higher score indicates higher disability	Day 1 and Day 35 ±4 and [Day 1 and Day 84 ±7
Secondary	secondary endpoint/safety	The description of all adverse events, related and unrelated to the medical devices, anticipated or unanticipated.	Day 1 and Day 84 ±7
Secondary	secondary endpoint/Investigator overall treatment satisfaction using by a four-point scale	The between group comparison using on a four-point scale assessing investigator's overall satisfaction on the treatment's clinical performance. The between group comparison using on a four-point scale assessing investigator's overall satisfaction on the treatment's clinical performance. Overall investigator' satisfaction of the product's clinical performance will be assessed at the end of the patient follow-up period on a four-point scale from 0: very satisfactory, 1: satisfactory; 2: somewhat unsatisfactory; 3: unsatisfactory Safety • The description of all adverse events, related and unrelated to the medical devices, anticipated or unanticipated.	Day 35±4 and Day 84 ±7